We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-3.45%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$334M
AUM Growth
-$21.5M
Cap. Flow
+$1.64M
Cap. Flow %
0.49%
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$3.77M
2
IPSC icon
Century Therapeutics
IPSC
+$3.65M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.89M
4
PRQR icon
ProQR Therapeutics
PRQR
+$2.88M
5
RVMD icon
Revolution Medicines
RVMD
+$2.41M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$5.56M
2
ETNB
89bio
ETNB
+$4.13M
3
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$3.65M
4
BHVN icon
Biohaven
BHVN
+$2.51M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNFT
51
DELISTED
Genfit
GNFT
$812K 0.24%
197,940
– –
MREO
52
Mereo BioPharma
MREO
$47.3M
$775K 0.23%
1,096,513
– –
SURF
53
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$769K 0.23%
1,100,000
+317,000
+40% +$257K
KPTI icon
54
Karyopharm Therapeutics
KPTI
$48M
$750K 0.22%
12,845
– –
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$710K 0.21%
265,878
– –
SPRB
56
Spruce Biosciences
SPRB
$129M
$690K 0.21%
+4,160
New +$773K
ACRV icon
57
Acrivon Therapeutics
ACRV
$74M
$649K 0.19%
51,148
+35,500
+227% +$596K
PRDS
58
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$633K 0.19%
479,386
– –
MASI
59
DELISTED
Masimo
MASI
$554K 0.17%
3,000
– –
KNTE
60
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$506K 0.15%
81,008
+10,000
+14% +$60.9K
RGLS
61
DELISTED
Regulus Therapeutics
RGLS
$471K 0.14%
555,555
– –
MDNA
62
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$416K 0.12%
660,000
– –
STRO icon
63
Sutro Biopharma
STRO
$421M
$391K 0.12%
+8,470
New +$538K
IMA
64
ImageneBio Inc
IMA
$64.6M
$390K 0.12%
9,411
-799
-8% -$36.7K
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
$383K 0.11%
351,064
– –
CMPX icon
66
Compass Therapeutics
CMPX
$387M
$382K 0.11%
116,882
-485,169
-81% -$1.9M
NXTC icon
67
NextCure
NXTC
$23.8M
$278K 0.08%
15,641
– –
LCTX icon
68
Lineage Cell Therapeutics
LCTX
$274M
$210K 0.06%
140,000
– –
INGN icon
69
Inogen
INGN
$164M
$187K 0.06%
15,000
– –
SPRO icon
70
Spero Therapeutics
SPRO
$73M
$181K 0.05%
125,000
– –
CGEN icon
71
Compugen
CGEN
$228M
$144K 0.04%
205,202
– –
REUN
72
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$8.7K ﹤0.01%
12,598
-35,081
-74% -$39.1K
AFMD
73
DELISTED
Affimed
AFMD
– –
-68,628
Closed -$851K
BDTX icon
74
Black Diamond Therapeutics
BDTX
$112M
– –
-97,500
Closed -$176K
BMEA icon
75
Biomea Fusion
BMEA
$91.3M
– –
-34,625
Closed -$292K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, DAFNA Capital Management held 83 positions worth $334M, down 6.1% from $355M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2023 filing shows 4 new, 23 increased, 12 reduced and 11 closed positions. Its largest new stake was ProQR Therapeutics: 940,582 shares worth $2M. The largest sale was Fate Therapeutics, an estimated $5.56M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2023 buy was ProQR Therapeutics: 940,582 shares worth $2M.
  • DAFNA Capital Management added most to Cytokinetics in Q1 2023, an estimated $3.77M increase.
  • DAFNA Capital Management's biggest Q1 2023 reduction was Biohaven, cutting an estimated $2.51M.
  • DAFNA Capital Management fully exited Fate Therapeutics in Q1 2023, selling an estimated $5.56M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $334M portfolio in Q1 2023.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q1 2023.
  • DAFNA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $334M.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.